Catálogo de publicaciones - libros

Palabras clave – provistas por la editorial

developmental; Anemia of chronic disease; neurodegeneration; supplementation; MHC; iron chelation therapy; osteoblast; serum biomarker; FeSO4; haptoglobin; prevention; brain development; pituitary; trauma; hepcidin; Alzheimer’s disease; chaotropes; social behavior; Africa; macrophage; anemia of inflammation; Tfr2; chelation; cardiomyocyte; IV iron therapy; Oxidative stress; treatment; chronic kidney disease; iron homeostasis; oxygen sensing; iron chelators; age-related macular degeneration (AMD); pharmaceutical targets; non-transferrin-bound iron (NTBI); iron dextran; pulmonary arterial hypertension; labile iron; low and middle income countries; ferroportin; gut microbiota; reducibility; non-HFE; oxidative stress; antitumor compound; senescence; electron transfer; nanotechnology; iron deficiency; neonatal period; heme oxygenase; hypoxia; Anemia; NCOA4; patient blood management; microbiome; anemia; iron mobilization; iron release; phlebotomy; peritoneal dialysis; Friedreich Ataxia; ferritin; CD8+ T cells; M cells; neurodegenerative disease; NaFeEDTA; vascular calcification; cinnamic acid derivatives; oral iron salts; lipid; acute lung injury; Iron-sulfur; Interleukin-6; neurodegeneration with brain iron accumulation; macrophages; erythroblastic islands; cystic fibrosis; neuroimmune responses; flavin nucleotide; hemopexin; Iron chelators; nutrient iron; developing countries; hereditary hypoferritinemia; iron; cancer; Indonesia; n/a; Hfe; HFE; chronic heart failure; iron supplementation; intestinal inflammation; TNF; chelators; hemolysis; children; pulmonary arterial smooth muscle cells; cytokines; didox; intravenous iron; T lymphocytes; colorectal cancer; infants; liver; ferritinophagy; hereditary hyperferritinemia; SCFA; rheumatoid arthritis; membrane interactions; Sucrosomial® iron; lung; Kupffer cell; iron chelation; erythrophagocytosis; acute kidney injury; neurophysiology; iron transporters; iron absorption; infection; ferroptosis; fluorescent iron chelator; neonatal; SNC; immunity; mycobacteria; non-haem iron; natural history; 3-hydroxy-4-pyridinone; haem; inflammation; bone homeostasis; cardiovascular disease; heme; heme homeostasis; protein binding; brain; iron deficiency anemia; Fe2+-chelating activity; bioengineering; Mek/Erk; Bmp/Smad; iron delivery; genetic hemochromatosis; osteoclast; histidine; rhodamine; COPD; hemorrhage; antibacterial activity; bacteria; SLC40A1; transferrin receptor; drug delivery; nanocage; soybean seed ferritin; pig; iron metabolism; kidney; innate immunity; cataracts syndrome; erythropoiesis; obesity; mucosal immunity; iron overload; fluorophore; binding ability; inflammatory bowel disease (IBD); osteoporosis; biomarker; bioavailability; adverse event profile; metabolism; iron-carbohydrate complex; kinetics; flavonoids; iron regulatory proteins; lung infection; non transferrin bound iron; central nurse macrophage; iron processing; malaria; neurodegenerative diseases; multifunctional iron chelators; retina; neuroinflammation; anti-hepcidin therapy; lung diseases; anaemia; RRM2; cognition; mitochondria; therapy; NBIA; red pulp macrophage; efficacy; hemochromatosis; tolerability; oral iron therapy; growth; venesections